Plain-language definitions for 155+ peptide and biochemistry terms.
Defined terms: 503A Pharmacy, 503B Outsourcing Facility, Acylation, Adverse Event, Aggregation, Aliquot, Amino Acid, Amino Acid Analysis (AAA), AMPK (AMP-Activated Protein Kinase), Amylin, Analogue, Anaphylaxis, Angiogenesis, Anti-Drug Antibodies (ADA), Apoptosis, Autophagy, Bacteriostatic Water, BDNF (Brain-Derived Neurotrophic Factor), Beyond-Use Date (BUD), Bioavailability, Biomarker, Bioregulator, Black Box Warning, Blood-Brain Barrier (BBB), Bulk Drug Substance, Cardiolipin, CAS Number, Certificate of Analysis (COA), cGMP (Current Good Manufacturing Practice), Class II Recall, Cold Chain, Compounded Medication, Contraindication, CREB (cAMP Response Element-Binding Protein), Cristae, Cyclization, D-Retro-Inverso, DAC (Drug Affinity Complex), Deamidation, Degradation Product, Desensitization, Desiccant, Diluent, Dose-Response Curve, Downregulation, Drug Interaction, Drug Shortage Declaration, EMA (European Medicines Agency), Endotoxin, Endpoint, Enteric Coating, Excipient, FDA Category 1, FDA Category 2, First-Pass Metabolism, Freeze-Thaw Cycle, Gallbladder Disease, Gastroparesis, Ghrelin, GHRH (Growth Hormone Releasing Hormone), GHRP (Growth Hormone Releasing Peptide), GHS-R1a (Growth Hormone Secretagogue Receptor), GIP (Glucose-Dependent Insulinotropic Polypeptide), GLP-1 (Glucagon-Like Peptide-1), Glucagon, Growth Hormone Secretagogue (GHS), Half-Life, HPLC (High-Performance Liquid Chromatography), Immunogenicity, In Vitro, In Vivo, INCI Name, Incretin, IND (Investigational New Drug), Injection Site Reaction, Injection Site Rotation, Insulin Syringe, Intramuscular (IM), Intranasal, Intranasal Delivery, Intravenous (IV), JAK/STAT Pathway, LAL Test (Limulus Amebocyte Lysate), Lipohypertrophy, Loading Dose, Lyophilization, Lyophilized, Maintenance Dose, Mannitol, MAPK/ERK Pathway, Mass Spectrometry (MS), MedWatch, Melanocortin Receptor, Meta-Analysis, MHRA (Medicines and Healthcare products Regulatory Agency), Microneedle Patch, Mitochondrial Biogenesis, Myostatin, Neuropeptide, NF-κB (Nuclear Factor Kappa B), Observational Study, Off-Label Use, Orphan Drug, Oxidation, p-Value, Pancreatitis, PCAC (Pharmacy Compounding Advisory Committee), PEGylation, PepT1 Transporter, Peptide, Peptide Blend, Peptide Bond, Peptide Stack, Pharmacodynamics, Pharmacokinetics, Phase I Trial, Phase II Trial, Phase III Trial, PI3K/AKT/mTOR Pathway, Placebo Effect, Preclinical, Publication Bias, Purity, Randomized Controlled Trial (RCT), Receptor Agonist, Receptor Antagonist, Reconstitution, REMS (Risk Evaluation and Mitigation Strategy), Research Use Only (RUO), SASP (Senescence-Associated Secretory Phenotype), Satellite Cells, Secretagogue, Senescent Cells, Senolytic, Sequence, Signaling Peptide, SNARE Complex, Sterile Abscess, Sterile Water, Sterility Testing, Subcutaneous (SubQ), Sublingual, Systematic Review, Tachyphylaxis, Telomerase, TGA (Therapeutic Goods Administration), Therapeutic Window, Third-Party Testing, Titration, Topical Peptide, Transdermal, USP (United States Pharmacopeia), Vial, WADA (World Anti-Doping Agency), Washout Period.